(NASDAQ: IPSC) Century Therapeutics's forecast annual revenue growth rate of 133.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Century Therapeutics's revenue in 2024 is $2,235,000.On average, 5 Wall Street analysts forecast IPSC's revenue for 2024 to be $601,120,861, with the lowest IPSC revenue forecast at $25,927,145, and the highest IPSC revenue forecast at $2,007,409,217. On average, 4 Wall Street analysts forecast IPSC's revenue for 2025 to be $869,337,179, with the lowest IPSC revenue forecast at $25,927,145, and the highest IPSC revenue forecast at $2,868,190,438.
In 2026, IPSC is forecast to generate $2,448,170,686 in revenue, with the lowest revenue forecast at $2,448,170,686 and the highest revenue forecast at $2,448,170,686.